Literature DB >> 11708764

Cervical dystonia pathophysiology and treatment options.

M Velickovic1, R Benabou, M F Brin.   

Abstract

Dystonia is a syndrome of sustained involuntary muscle contractions, frequently causing twisting and repetitive movements or abnormal posturing. Cervical dystonia (CD) is a form of dystonia that involves neck muscles. However, CD is not the only cause of neck rotation. Torticollis may be caused by orthopaedic, musculofibrotic, infectious and other neurological conditions that affect the anatomy of the neck, and structural causes. It is estimated that there are between 60,000 and 90,000 patients with CD in the US. The majority of the patients present with a combination of neck rotation (rotatory torticollis or rotatocollis), flexion (anterocollis), extension (retrocollis), head tilt (laterocollis) or a lateral or sagittal shift. Neck posturing may be either tonic, clonic or tremulous, and may result in permanent and fixed contractures. Sensory tricks ('geste antagonistique') often temporarily ameliorate dystonic movements and postures. Commonly used sensory tricks by patients with CD include touching the chin, back of the head or top of the head. Patients with CD are classified according to aetiology into two groups: primary CD (idiopathic--may be genetic or sporadic) or secondary CD (symptomatic). Patients with primary CD have no evidence by history, physical examination or laboratory studies (except primary dystonia gene) of any secondary cause for the dystonic symptoms. CD is a part of either generalised or focal dystonic syndrome which may have a genetic basis, with an identifiable genetic association. Secondary or symptomatic CD may be caused by central or peripheral trauma, exposure to dopamine receptor antagonists (tardive), neurodegenerative disease, and other conditions associated with abnormal functioning of the basal ganglia. In the majority of patients with CD, the aetiology is not identifiable and the disorder is often classified as primary. Unless the aetiological investigation reveals a specific therapeutic intervention, therapy for CD is symptomatic. It includes supportive therapy and counselling, physical therapy, pharmacotherapy, chemodenervation [botulinum toxin (BTX), phenol, alcohol], and central and peripheral surgical therapy. The most widely used and accepted therapy for CD is local intramuscular injections of BTX-type A. Currently, both BTX type A and type B are commercially available, and type F has undergone testing. Pharmacotherapy, including anticholinergics, dopaminergic depleting and blocking agents, and other muscle relaxants can be used alone or in combination with other therapeutic interventions. Surgery is usually reserved for patients with CD in whom other forms of treatment have failed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708764     DOI: 10.2165/00003495-200161130-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  204 in total

Review 1.  State legislative efforts to regulate use and potential misuse of genetic information.

Authors:  J E McEwen; P R Reilly
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

2.  Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A.

Authors:  A Brashear; K Bergan; J Wojcieszek; E R Siemers; W Ambrosius
Journal:  Mov Disord       Date:  2000-01       Impact factor: 10.338

3.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

4.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  Increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia.

Authors:  G Becker; D Berg; W D Rausch; H K Lange; P Riederer; K Reiners
Journal:  Ann Neurol       Date:  1999-08       Impact factor: 10.422

6.  Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia.

Authors:  T Ansved; T Odergren; K Borg
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

7.  TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease.

Authors:  P Shashidharan; P F Good; A Hsu; D P Perl; M F Brin; C W Olanow
Journal:  Brain Res       Date:  2000-09-22       Impact factor: 3.252

8.  Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.

Authors:  P Greene; H Shale; S Fahn
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

9.  Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene.

Authors:  H Ichinose; T Ohye; E Takahashi; N Seki; T Hori; M Segawa; Y Nomura; K Endo; H Tanaka; S Tsuji
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

10.  Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.

Authors:  P E Greene; S Fahn
Journal:  Mov Disord       Date:  1993-10       Impact factor: 10.338

View more
  9 in total

Review 1.  The effectiveness of physiotherapy for cervical dystonia: a systematic literature review.

Authors:  Joke De Pauw; Kevin Van der Velden; Jill Meirte; Ulrike Van Daele; Steven Truijen; Patrick Cras; Rudy Mercelis; Willem De Hertogh
Journal:  J Neurol       Date:  2014-01-12       Impact factor: 4.849

2.  Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study.

Authors:  Vijay P Misra; Edvard Ehler; Benjamin Zakine; Pascal Maisonobe; Marion Simonetta-Moreau
Journal:  BMJ Open       Date:  2012-06-14       Impact factor: 2.692

Review 3.  Botulinum toxin A (Dysport®): in dystonias and focal spasticity.

Authors:  Susan J Keam; Victoria J Muir; Emma D Deeks
Journal:  Drugs       Date:  2011-05-28       Impact factor: 11.431

4.  AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis.

Authors:  Seye Abogunrin; Sarah Brand; Kamal Desai; Jerome Dinet; Sylvie Gabriel; Timothy Harrower
Journal:  Clinicoecon Outcomes Res       Date:  2015-09-09

Review 5.  The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions - An evidence based review.

Authors:  Kamran Habib Awan
Journal:  Saudi Pharm J       Date:  2016-04-30       Impact factor: 4.330

6.  Alterations of Interhemispheric Functional Connectivity and Degree Centrality in Cervical Dystonia: A Resting-State fMRI Study.

Authors:  Wenyan Jiang; Yiwu Lei; Jing Wei; Lu Yang; Shubao Wei; Qiong Yin; Shuguang Luo; Wenbin Guo
Journal:  Neural Plast       Date:  2019-04-24       Impact factor: 3.599

7.  Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis.

Authors:  Gavin Charlesworth; Vincent Plagnol; Kira M Holmström; Jose Bras; Una-Marie Sheerin; Elisavet Preza; Ignacio Rubio-Agusti; Mina Ryten; Susanne A Schneider; Maria Stamelou; Daniah Trabzuni; Andrey Y Abramov; Kailash P Bhatia; Nicholas W Wood
Journal:  Am J Hum Genet       Date:  2012-11-29       Impact factor: 11.025

8.  An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions.

Authors:  Ricardo Persaud; George Garas; Sanjeev Silva; Constantine Stamatoglou; Paul Chatrath; Kalpesh Patel
Journal:  JRSM Short Rep       Date:  2013-02-12

9.  An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport).

Authors:  H Hefter; R Benecke; F Erbguth; W Jost; G Reichel; J Wissel
Journal:  BMJ Open       Date:  2013-04-18       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.